More positive data for Zolgensma in spinal muscular atrophy

24 March 2020
novartis_tower_large

Data published at a virtual Clinical Trial Session, conducted by the Muscular Dystrophy Association (MDA), show Zolgensma (onasemnogene abeparvovec-xioi) produced significant benefit to people with spinal muscular atrophy (SMA).

The data, which are drawn from a range of studies, are being presented virtually after the 2020 MDA Annual Conference was cancelled, due to the recent COVID-19 outbreak.

Novartis (NOVN: VX) company AveXis presented the data, which includes patients treated pre-symptomatically, and showed sustained durability in patients now up to five years post-dosing and some patients more than five years of age.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology